<DOC>
	<DOCNO>NCT03010059</DOCNO>
	<brief_summary>The purpose study assess rate extent absorption JNJ-64041575 measure ALS-008112 plasma concentration follow administration single oral dose JNJ-64041575 give 2 new concept formulation ( oral suspension tablet ) compare respective current formulation fast condition assess effect food pharmacokinetics 2 new concept formulation feed condition healthy adult participant .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability JNJ64041575 Administered 2 Different New Concept Formulations ( Oral Suspension Tablet ) Compared Their Respective Current Formulations , Assess Effect Food Pharmacokinetics 2 New Concept Formulations</brief_title>
	<detailed_description />
	<criteria>Participant must body mass index ( BMI ; weight kg divide square height meter ) 18.0 30.0 kilogram per square meter kg/m^2 , extremes include , body weight less 50.0 kg , extremes include Participant must normal 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function screening , include : ) normal sinus rhythm ( heart rate 45 100 beat per minute [ bpm ] , extremes include ) ; b ) QT correct accord Fridericia 's formula ( QTcF ) interval less equal ( &lt; = ) 430 millisecond ( m ) male participant &lt; =450 m female participant ; c ) QRS interval &lt; =110 m ; ) PR interval &lt; =200 m ; e ) ECG morphology consistent healthy cardiac conduction function . Any evidence heart block , leave right bundle branch block exclusionary Participants must normal value alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ( less equal ( &lt; = ) 1.0Ã—upper limit laboratory normal range [ ULN ] ) Contraceptive use female participant consistent local regulation regard use contraceptive method participant participate clinical study . Before randomization , woman must either : ) Not childbearing potential define : 1 ) Postmenopausal : A postmenopausal state define great ( &gt; ) 45 year menses 12 consecutive month without alternative medical cause serum follicle stimulate hormone ( FSH ) level postmenopausal range ( &gt; 40 International unit per liter [ IU/L ] milliinternational unit per milliliter [ mIU/mL ] ) , OR ; 2 ) Permanently sterile : Permanent sterilization method include hysterectomy , bilateral salpingectomy , bilateral tubal occlusion/ligation procedure ( without reversal operation ) , bilateral oophorectomy b ) Of childbearing potential , heterosexually active , 1 ) Practicing highly effective method contraception ( failure rate less ( &lt; ) 1percent ( % ) per year use consistently correctly ) 2 ) Agrees remain highly effective method throughout study least 44 day last dose study drug A female participant , except postmenopausal , must negative serum beta human chorionic gonadotropin ( beta hCG ) pregnancy test screening , negative urine pregnancy test Day 1 treatment period Participant must able taste smell normally , opinion . Participants impaired sense taste and/or smell due condition allergic rhinitis , common cold , sinusitis eligible take part study Participant mouth pathology include , limited , pain , ulcer , edema , mucosal erosion , gingivitis and/or ( dental ) abscess , receive treatment oral pathology ( eg , antifungal antibiotic ) oral treatment disease Participant history clinically significant drug allergy , limited , sulfonamides penicillin , drug allergy diagnose previous study experimental drug Participant hepatitis B surface antigen ( HBsAg ) positive hepatitis C virus ( HCV ) antibody positive HCV RNA positive , another clinically active liver disease screen Participant history human immunodeficiency virus type 1 ( HIV1 ) HIV 2 antibody positive , test positive HIV1 2 screen Participant previously dose JNJ64041575 3 singledose study JNJ64041575 previously dose JNJ64041575 multipledose study JNJ64041575 Participants 1 follow laboratory abnormality screen defined Division Microbiology Infectious Diseases ( DMID ) Adult Toxicity Table ) Serum creatinine grade 1 great ( great [ &gt; ] 1.0* upper limit laboratory normal range [ ULN ] ) b ) Hemoglobin grade 1 great ( &lt; =10.5 gram per decilitre [ g/dL ] ) c ) Platelet count grade 1 great ( &lt; =99.999/millimeter [ mm ] ^3 ) ) Reticulocyte count ( absolute ) low limit laboratory normal range ( LLN ) e ) Absolute neutrophil count grade 1 great ( &lt; =1,500/mm^3 ) f ) Total bilirubin grade 1 great ( &gt; 1.0*ULN ) g ) Any toxicity grade 2 , except grade 2 elevation low density lipoprotein ( LDL ) cholesterol and/or cholesterol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>